WO2014005421A1 - 苯并间二氧杂环戊烯衍生物及其制备方法和用途 - Google Patents
苯并间二氧杂环戊烯衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- WO2014005421A1 WO2014005421A1 PCT/CN2013/000813 CN2013000813W WO2014005421A1 WO 2014005421 A1 WO2014005421 A1 WO 2014005421A1 CN 2013000813 W CN2013000813 W CN 2013000813W WO 2014005421 A1 WO2014005421 A1 WO 2014005421A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ethyl
- piperidinyl
- isoindole
- compound
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract description 35
- 150000005528 benzodioxoles Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 166
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 20
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 128
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 claims description 70
- 125000003003 spiro group Chemical group 0.000 claims description 66
- 238000006243 chemical reaction Methods 0.000 claims description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- -1 cyclodecyl Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical group 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- MQUPWTBHHPUUMC-UHFFFAOYSA-N isoindole Chemical compound C1=CC=C[C]2C=NC=C21 MQUPWTBHHPUUMC-UHFFFAOYSA-N 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 14
- 125000006239 protecting group Chemical group 0.000 claims description 14
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 14
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- SOWOYMBNJVLWGP-UHFFFAOYSA-N isoindol-5-one Chemical compound O=C1C=CC2=CN=CC2=C1 SOWOYMBNJVLWGP-UHFFFAOYSA-N 0.000 claims description 13
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 12
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 12
- NQBUERYLUPYOEL-UHFFFAOYSA-N isoindol-4-one Chemical compound O=C1C=CC=C2C=NC=C12 NQBUERYLUPYOEL-UHFFFAOYSA-N 0.000 claims description 12
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000006612 decyloxy group Chemical group 0.000 claims description 11
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 150000001721 carbon Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 10
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 9
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- BPBPYQWMFCTCNG-UHFFFAOYSA-N 2-(butan-2-yldisulfanyl)-1H-imidazole Chemical compound CCC(C)SSC1=NC=CN1 BPBPYQWMFCTCNG-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical group [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 3
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- YZHTTYDRIVKOGU-UHFFFAOYSA-N indole-5,7-dione Chemical compound O=C1CC(=O)C2=NC=CC2=C1 YZHTTYDRIVKOGU-UHFFFAOYSA-N 0.000 claims description 3
- OUJCNSMETCJDJZ-UHFFFAOYSA-N isoindole-4,6-dione Chemical compound C=1N=CC2=CC(CC(C12)=O)=O OUJCNSMETCJDJZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 239000007818 Grignard reagent Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims description 2
- 230000003197 catalytic effect Effects 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001717 carbocyclic compounds Chemical class 0.000 claims 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 7
- 229960004373 acetylcholine Drugs 0.000 abstract description 7
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 108090000371 Esterases Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 59
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 52
- 229960003135 donepezil hydrochloride Drugs 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 241001465754 Metazoa Species 0.000 description 28
- 238000002474 experimental method Methods 0.000 description 27
- 238000012347 Morris Water Maze Methods 0.000 description 21
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 18
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 18
- 229960002646 scopolamine Drugs 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 239000007858 starting material Substances 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 210000003140 lateral ventricle Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000005481 NMR spectroscopy Methods 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 206010027175 memory impairment Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- ISXSUKUXUPLGTD-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(5-oxopyrrolidin-2-yl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2NC(CC2)=O)C=CC=1 ISXSUKUXUPLGTD-UHFFFAOYSA-N 0.000 description 7
- 102000012440 Acetylcholinesterase Human genes 0.000 description 7
- 108010022752 Acetylcholinesterase Proteins 0.000 description 7
- 229940022698 acetylcholinesterase Drugs 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 7
- 0 *CN1CCC(CCN(C(*)(c2c3cc4OCOc4c2)I)C3=O)CC1 Chemical compound *CN1CCC(CCN(C(*)(c2c3cc4OCOc4c2)I)C3=O)CC1 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 6
- 238000011047 acute toxicity test Methods 0.000 description 6
- 239000012065 filter cake Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 5
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 4
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ABRVLXLNVJHDRQ-UHFFFAOYSA-N [2-pyridin-3-yl-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound FC(C1=CC(=CC(=N1)C=1C=NC=CC=1)CN)(F)F ABRVLXLNVJHDRQ-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229960003530 donepezil Drugs 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229940118019 malondialdehyde Drugs 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- FMCAFXHLMUOIGG-JTJHWIPRSA-N (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-JTJHWIPRSA-N 0.000 description 3
- LIDBMZYKSAXTQG-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-sulfamoylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(N)(=O)=O)C=CC=1 LIDBMZYKSAXTQG-UHFFFAOYSA-N 0.000 description 3
- SONNQRNOTIAJDS-GFCCVEGCSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(2R)-2,3-dihydroxypropyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NC[C@H](CO)O)C=CC=1 SONNQRNOTIAJDS-GFCCVEGCSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- LJHFUFVRZNYVMK-ZDUSSCGKSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3S)-3-hydroxypyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@H](CC1)O LJHFUFVRZNYVMK-ZDUSSCGKSA-N 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 150000003233 pyrroles Chemical class 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- KORIJXKQGMTQTO-UHFFFAOYSA-N 1h-pyrrol-2-ylmethanol Chemical compound OCC1=CC=CN1 KORIJXKQGMTQTO-UHFFFAOYSA-N 0.000 description 2
- JPMRGPPMXHGKRO-UHFFFAOYSA-N 2-(chloromethyl)pyridine hydrochloride Chemical compound Cl.ClCC1=CC=CC=N1 JPMRGPPMXHGKRO-UHFFFAOYSA-N 0.000 description 2
- BVKRPQCDGACLPX-UHFFFAOYSA-N 2-[4-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyindol-1-yl]-N-methyl-N-phenylacetamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC1=C2C=CN(C2=CC=C1)CC(=O)N(C1=CC=CC=C1)C BVKRPQCDGACLPX-UHFFFAOYSA-N 0.000 description 2
- YITHZLOMDXHKDT-UHFFFAOYSA-N 3-(bromomethyl)pyridazine;hydrobromide Chemical compound Br.BrCC1=CC=CN=N1 YITHZLOMDXHKDT-UHFFFAOYSA-N 0.000 description 2
- GDSLUYKCPYECNN-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[(4-fluorophenyl)methyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCC2=CC=C(C=C2)F)C=CC=1 GDSLUYKCPYECNN-UHFFFAOYSA-N 0.000 description 2
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 2
- 101100132433 Arabidopsis thaliana VIII-1 gene Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- GXFIJNNOECYQOJ-UHFFFAOYSA-N [2-[1-(1-methylpyrazol-4-yl)indol-4-yl]oxy-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound CN1N=CC(=C1)N1C=CC2=C(C=CC=C12)OC1=NC(=CC(=C1)CN)C(F)(F)F GXFIJNNOECYQOJ-UHFFFAOYSA-N 0.000 description 2
- KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- ZSKGQVFRTSEPJT-UHFFFAOYSA-N pyrrole-2-carboxaldehyde Chemical compound O=CC1=CC=CN1 ZSKGQVFRTSEPJT-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- VJLYHTOSFSGXGH-CQSZACIVSA-N (2R)-1-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2[C@H](CCC2)C(=O)O)C=CC=1 VJLYHTOSFSGXGH-CQSZACIVSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- ZWHOTPNCEFWATE-CQSZACIVSA-N (3R)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-CQSZACIVSA-N 0.000 description 1
- ZWHOTPNCEFWATE-AWEZNQCLSA-N (3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-AWEZNQCLSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GJUKLBGQYOWYBA-UHFFFAOYSA-N 1,2-diiodoguanidine Chemical compound [H]N(I)C(=N)N([H])I GJUKLBGQYOWYBA-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical class C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- VTNULXUEOJMRKZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2H-tetrazol-5-ylmethyl)benzamide Chemical compound N=1NN=NC=1CNC(C1=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)=O VTNULXUEOJMRKZ-UHFFFAOYSA-N 0.000 description 1
- MZSAMHOCTRNOIZ-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylaniline Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(NC2=CC=CC=C2)C=CC=1 MZSAMHOCTRNOIZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000012181 Alzheimer disease 13 Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- HWRXKEXCROEGNX-UHFFFAOYSA-N CC(C)(C)OC(N1CCC(CCN(C(c2c3cc4OCOc4c2)=O)C3=O)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(CCN(C(c2c3cc4OCOc4c2)=O)C3=O)CC1)=O HWRXKEXCROEGNX-UHFFFAOYSA-N 0.000 description 1
- DATWIJDGGJOFAI-UHFFFAOYSA-N CC(c(cc1OC)c2cc1OC)N(CCC1CCNCC1)C2=O Chemical compound CC(c(cc1OC)c2cc1OC)N(CCC1CCNCC1)C2=O DATWIJDGGJOFAI-UHFFFAOYSA-N 0.000 description 1
- LLKPHLHJWLBDOL-UHFFFAOYSA-N CC(c1c2cc3OCOc3c1)N(CCC1CCN(Cc3ccccc3)CC1)C2=O Chemical compound CC(c1c2cc3OCOc3c1)N(CCC1CCN(Cc3ccccc3)CC1)C2=O LLKPHLHJWLBDOL-UHFFFAOYSA-N 0.000 description 1
- 102000017926 CHRM2 Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150012960 Chrm2 gene Proteins 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- UFUPZWXIOILTGP-UHFFFAOYSA-N ClNC(=NCl)Cl Chemical compound ClNC(=NCl)Cl UFUPZWXIOILTGP-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- PPEKNFCWICMAAE-UHFFFAOYSA-N O=C(c1c2)N(CCC3CCN(Cc4ccccc4)CC3)C3(CC3)c1cc1c2O[IH]O1 Chemical compound O=C(c1c2)N(CCC3CCN(Cc4ccccc4)CC3)C3(CC3)c1cc1c2O[IH]O1 PPEKNFCWICMAAE-UHFFFAOYSA-N 0.000 description 1
- FBXITQYYIIIIKP-UHFFFAOYSA-N O=C(c1c2cc3OCOc3c1)N(CCC1CCNCC1)C2=O Chemical compound O=C(c1c2cc3OCOc3c1)N(CCC1CCNCC1)C2=O FBXITQYYIIIIKP-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000003927 aminopyridines Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RIUNZXNCMZMRMP-UHFFFAOYSA-N ethyl 5-methyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)C1=CC=C(C)N1 RIUNZXNCMZMRMP-UHFFFAOYSA-N 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000000752 ionisation method Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- NRUBUZBAZRTHHX-UHFFFAOYSA-N lithium;propan-2-ylazanide Chemical compound [Li+].CC(C)[NH-] NRUBUZBAZRTHHX-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000012463 white pigment Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Definitions
- the present invention relates to a novel class of benzodioxol derivatives which have acetylcholinesterase inhibitory activity and which can be used For the treatment or prevention of Alzheimer's disease.
- the invention also relates to a process for the preparation of such compounds. BACKGROUND OF THE INVENTION With the rapid growth of the elderly population, the number of people suffering from Alzheimer's disease has also increased dramatically. Alzheimer's disease is also known as the Alzheimer type dementia or the senile dementia of the Alzheimer type.
- Alzheimer's disease is the most common type of Alzheimer's disease. It has become the sixth leading cause of death in the United States and the fifth leading cause of death among Americans aged 65 and over. Although scientists have conducted extensive and in-depth research on this disease, to date, the exact cause of the disease remains unclear. Alzheimer's disease is a progressive disease that constantly kills nerve cells, destroys nerve connections in the brain, and causes tissue in the brain to be destroyed, causing patients to gradually lose memory, consciousness, and judgment, and cause The patient developed emotional disorders and behavioral disorders.
- Alzheimer's disease is an irreversible disease, and there is no medicine to prevent it, and no medicine can cure it or delay the progression of it.
- the drugs currently used to treat the disease can only alleviate or ameliorate the symptoms of the disease.
- Acetylcholine is a neurotransmitter that is a chemical released by the nerves. If the system that produces acetylcholine in the brain, the cholinergic system is damaged, it can cause Alzheimer's disease. Memory impairment; and the function of acetylcholinesterase is to catalyze the hydrolysis of acetylcholine, ie, acetylcholine.
- acetylcholinesterase inhibitors include donepezil and tacrine. , rivastigmine and galantamine, wherein donepezil (Sugimoto et al. US4895841 and 5100901; Pathi et al. WO 2007077443; Parthasaradhi et al. WO 2005003092; Dubey et al.
- WO 2005076749; Gutman Et al. WO 200009483; Sugimoto et al. J. Med. Chem. 1995, 38, 481 ) is a first-line treatment for Alzheimer's disease.
- donepezil and the other four drugs only improve the patient's symptoms, and this is only a temporary improvement in symptoms, only lasting about 6-12 months, and the patient's response rate to these drugs is only About 50% (Alzheimer's Association, 201 1 Alzheimer' Disease Facts and Figures, Alzheimer's & Dementia, 201 1, 7(2), 208).
- the present invention provides a novel class of acetylcholinesterase inhibitors, which are a new class of benzodioxole derivatives, which are more effective than donepezil and have less side effects for the treatment of Alzheimer's disease. drug.
- SUMMARY OF THE INVENTION One object of the present invention is to disclose a novel class of acetylcholinesterase inhibitors - benzodioxole derivatives or pharmaceutically acceptable salts thereof.
- the compounds of the present invention can be represented by the formula (I):
- A is selected from the group consisting of phenyl, R 3 substituted phenyl, pyridyl, R 4 substituted pyridyl, pyrimidinyl, R 5 substituted pyrimidinyl, pyrrolyl, R 6 substituted pyrrolyl, pyridazinyl R 7 substituted pyridazinyl, pyrazolyl or R 8 substituted pyrazolyl;
- R 3 is 1 to 5 substituents independently selected from the group consisting of halogen, (-C 3 ) fluorenyl, (C 2 -C 3 ) alkenyl, (C 3 -C 4 )cyclodecyl, ( D-C 3 ) alkoxy, trifluoromethyl or cyano;
- R 4 is 1 to 4 substituents independently selected from the group consisting of: halogen, (C, -C 3 ) fluorenyl, (C 2 - C 3 ) alkenyl, (C 3 - C 4 ) cyclodecyl , (-) alkoxy, trifluoromethyl or cyano;
- R 5 is 1 to 3 substituents independently selected from the group consisting of halogen, (-Cs) fluorenyl, (C 2 - C 3 ) alkenyl, (C 3 -C 4 )cyclodecyl, (d - C 3 ) decyloxy, trifluoromethyl or cyano;
- R 6 is 1 to 4 substituents independently selected from the group consisting of: (dC 3 ) anthracenyl, (C 2 -C 3 ) alkenyl or (C 3 -C 4 )cycloalkyl;
- R 7 is 1 to 3 substituents independently selected from the group consisting of halogen, (dC 3 ) alkyl, (C 2 -C 3 ) alkenyl, (C 3 - C 4 )cyclodecyl, (Cr "C 3 ) methoxy, trifluoromethyl or cyano;
- R 8 is 1 to 3 substituents independently selected from the group consisting of: (dC 3 ) alkyl, (C 2 -C 3 ) alkenyl or (C 3 -C 4 )cycloalkyl;
- A is preferably selected from phenyl, R 3 is substituted phenyl, pyridyl, R 4 is a substituted pyridinyl, pyrimidinyl or pyrimidinyl substituted with R 5.
- A is preferably a phenyl group wherein the above, R 3 is substituted phenyl, pyridyl, R 4 is a substituted pyridinyl, pyrimidinyl, R 5 substituted pyrimidinyl, pyrrolyl, R 6 substituted pyrrole a pyridazine group, a R 7 -substituted pyridazinyl group, a pyrazolyl group, an R 8 -substituted pyrazolyl group; wherein R 3 is 1 to 5 substituents, preferably from the group: halogen, (C "C 3 An alkyl group, (dC 3 ) decyloxy group, trifluoromethyl group or cyano group; R 4 is 1 to 4 substituents, preferably from the group: halogen, (d-Cs) fluorenyl, (dC 3 ) ⁇ oxy, trifluoromethyl or cyano; R 5 is 1 to
- R 3 is substituted phenyl, pyridyl, pyrimidinyl, pyrrolyl, R 6 substituted pyrrolyl, pyridazinyl, or pyrazolyl; wherein R 3 1 to 5 substituents, preferably From the following groups: halogen, (CH3 ⁇ 4) fluorenyl, (-C3) alkoxy, trifluoromethyl or cyano; R 6 is 1 to 4 substituents, preferably from (dC 3 ) fluorenyl.
- A is phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2-pyridyl, 3-pyridyl, pyrimidine-2 -yl, pyrrol-2-yl, 5-methylpyrrol-2-yl, pyridazin-3-yl or pyrazol-5-yl. More specifically, the compound (I) wherein the compound is selected from the group consisting of:
- the compound is:
- R 1 and R 2 are as defined above;
- R 9 is a protecting group for an amino group, preferably tert-butoxycarbonyl (Boc); a compound of formula H, or a salt thereof -
- the salt refers to a salt formed with an acid.
- the acid is selected from the group consisting of hydrochloric acid, sulfuric acid, trifluoroacetic acid and the like.
- a second aspect of the invention discloses the use of a compound of formula (I) and a pharmaceutical composition thereof for the manufacture of a medicament for the treatment or prevention of a disease associated with an acetylcholinesterase inhibitor.
- a further aspect of the invention resides in the use of a compound of formula (I) for the manufacture of a medicament for the treatment of Alzheimer's disease.
- Another aspect of the invention resides in a pharmaceutical composition comprising an effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof.
- Pharmaceutically acceptable carriers compatible with the compounds of formula (I) may also be included in the pharmaceutical compositions of the invention.
- the compound of the formula (1) can be administered in a general dosage form, such as an oral dosage form and an injection dosage form, including capsules, tablets, powders, cachets, suspensions and solutions, preferably in an oral dosage form, more preferably. Administration is carried out in tablets and capsules in oral dosage forms.
- the dosage form and pharmaceutical compositions can be prepared using conventional pharmaceutically acceptable excipients and additives, as well as conventional techniques.
- the pharmaceutically acceptable excipients and additives include non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, thickeners, coloring agents. Agent, emulsifier, etc.
- a second object of the present invention is to disclose a process for the preparation of the benzodioxole derivative (Formula I).
- the method comprises: reacting a compound of the formula II or a salt thereof with a compound represented by the formula HI-1 or IH-2 to obtain:
- R 1 R 2 and A are as defined above;
- X is a halogen or a hydroxyl group, and Y is a formyl group or a fluorenyloxy group.
- A is a pyrrole or a substituted pyrrole, and the reaction is carried out under basic conditions (sodium alkoxide, potassium alkoxide or sodium/alcohol);
- Y is a fluorenyloxycarbonyl group, A is a pyrrole or a substituted pyrrole, with sodium/ The alcohol promotes the reaction.
- the compound of the formula II or a salt thereof can be prepared by a process comprising: removing an amino-protecting group of the compound of the formula IV: Wherein R 1 and R 2 are as defined above; R 9 is a protecting group for an amino group, preferably tert-butoxycarbonyl (Boc).
- the invention also provides a method for formulating a compound of formula (I) with an acid: that is, the compound of formula (I) is thoroughly mixed with a corresponding acid (such as hydrochloric acid, sulfuric acid, phosphoric acid, etc.), and post-treated to obtain a corresponding salt, such as preparation.
- a corresponding acid such as hydrochloric acid, sulfuric acid, phosphoric acid, etc.
- the third object of the present invention is to disclose a method for preparing an intermediate (Formula IV) involved in the invention.
- R 9 is a protecting group for an amino group, preferably a tert-butoxycarbonyl group (Boc); and R 1Q is a halogen or p-toluenesulfonyloxy group.
- a further aspect of the present invention provides a method for reducing a compound represented by the formula IV-1 to an alcohol by using the compound IV-1 as a raw material, and then converting the formed hydroxyl group into an easily acetyl group.
- the oxy group is finally subjected to catalytic hydrogenolysis to remove the acetoxy group to obtain a compound of the formula (IV-2) (shown as the following Reaction Scheme 2).
- This method is applicable to the case where both R 1 and R 2 are hydrogen in the compound of the formula (IV).
- R 9 is a protecting group for an amino group, preferably a tert-butoxycarbonyl group (Boc).
- a further aspect of the present invention provides a monomethylation of a benzylic group (i.e., a CH 2 group of a 5-membered lactam) of the compound of the formula IV-2 with the compound IV-2 as a starting material to give a compound of the formula (IV).
- the method of -3 (shown in the following reaction formula 3). This method is applicable to the case where R 1 is a methyl group or an ethyl group and R 2 is hydrogen in the compound of the formula (IV).
- R 9 is a protecting group for an amino group, preferably a tert-butoxycarbonyl group (Boc).
- a further aspect of the present invention provides a benzylation of a compound of the formula IV-3 (i.e., a carbon atom bonded to R 1 ) using the compound IV-3 as a starting material to obtain a compound of the formula (IV).
- the method of -4 ) (shown in the following Reaction Scheme 4). This method is applicable to the case where R 1 and R 2 are a methyl group or an ethyl group in the compound of the formula (IV).
- R 9 is a protecting group for an amino group, preferably a tert-butoxycarbonyl group (Boc).
- a further aspect of the present invention provides a method for reacting a compound represented by the formula IV-1 with a methyl Grignard reagent to form an alcohol, and then dehydrating the alcohol to an alkene under acidic conditions, and finally producing the compound IV-1.
- Carbon carbon The double bond is converted into a three-membered ring with Et 2 Zn/TFA/CH 2 I 2 to give a method of the compound of the formula (IV-5) (shown in the following Reaction Scheme 5).
- This method is applicable to the case where R 1 and R 2 in the compound of formula (IV) are cyclized together with the carbon atom to which they are attached to form a three-membered carbocyclic ring.
- R 9 is a protecting group for an amino group, preferably a tert-butoxycarbonyl group (Boc); and X is a halogen.
- Halogen means fluorine, chlorine, bromine and iodine.
- Mercapto as a group means a straight or branched saturated aliphatic hydrocarbon group.
- Mercapto groups include methyl, ethyl, n-propyl and 2-propyl.
- Alkenyl as a group refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond, which may be straight or branched. (C 2 -C 3 ) Alkenyl includes vinyl, propenyl, isopropenyl and allyl.
- Cycloalkyl means a saturated carbocyclic ring.
- the cyclodecyl group includes a cyclopropyl group and a cyclobutyl group.
- the three-membered ring has the same meaning as the three-membered carbocyclic ring, and all refer to a cyclopropyl ring, that is, both R 1 and R 2 are CH 2 , and the two are linked by a single carbon-carbon bond.
- Alkoxy means a group of (fluorenyl-0-). Among them, the sulfhydryl group is as defined above. (dC 3 ) Alkoxy includes methoxy, ethoxy, JH propoxy and isopropoxy.
- pharmaceutically acceptable salt refers to certain salts of the above compounds which retain their original biological activity and are suitable for medical use.
- the pharmaceutically acceptable salt of the compound represented by the formula (I) may be a salt formed with a suitable acid, and the suitable acid includes an inorganic acid and an organic acid such as acetic acid, benzenesulfonic acid, benzoic acid, camphor.
- the glassware is dried in an oven and/or heated to dryness.
- the reaction was followed by glass silica gel-60 F254 plate (0.25 mm) (TLC).
- Analytical thin layer chromatography was carried out in an appropriate solvent ratio (Wv). The end point of the reaction was taken as the starting material was depleted on the TLC.
- Mass spectrometry was measured by LC/MS, and the ionization method was ESI or APCI.
- Figure 1 is a plasma drug concentration-time curve after oral administration of donepezil hydrochloride, 1-33 and 1-35 to rats (the abscissa is time, the unit is h; the ordinate is the concentration, the unit is nmol/L).
- Example 1 4-[2-(5,7-Dioxo-[1,3]dioxol[4,5-1]isoindol-6-yl)ethyl]piperidine Preparation of small carboxylic acid tert-butyl ester (Compound XI)
- Example 8 4-[2-(5-Acetoxy-7-oxo-5H-[1,3]dioxol[4,5-f]isoindol-6-yl) Preparation of tert-butyl ethyl]piperidine-1-carboxylate (compound VHI-1)
- IM VIII-1 Into a 500 ml reaction flask, add 55 g (0.136 mol) of compound VH-1, 385 ml of dichloromethane, 43 ml (0.31 mol) of triethylamine, 1.8 g (0.015 mol) of 4-dimethyl The aminopyridine was stirred, and 31 ml (0.33 mol) of acetic anhydride was added thereto, and the mixture was reacted at room temperature for 1 hour, washed with 200 ml of water, and the organic layer was collected, dried over sodium sulfate, filtered, and the filtrate was concentrated to dryness to give about 79 g of compound VHI-1 , did not do a purification, directly used in the next page.
- Example 28 4-[2-(5-Oxospiro[[1,3]dioxol[4,5-f]isoindole-7,-cyclopropane] -6 -preparation of tert-butyl ester of ethyl]piperidine-1-carboxylate (Compound XV)
- Example 46 6-[2-[l-(2-Pyridylmethyl)-4-piperidinyl]ethyl]spiro[[1,3]dioxol[4,5-f Preparation of isoindole-7, fluorene-cyclopropane]-5-one hydrochloride (Compound 1-33)
- Example 48 6-[2-[l-(2-Pyridylmethyl)-4-piperidinyl]ethyl]spiro[[1,3]dioxol[4,5-f Preparation of isoindole-7, hydrazine-cyclopropene]-5-ketophosphate (compound I-3S)
- Example 49 6-[2-[l-(2-Pyridylmethyl)-4-piperidinyl]ethyl]-[1,3]dioxole[4,5-f] Preparation of indole-5,7-dione (compound 1-36)
- Example 50 6-[2-[l-(Pyridazin-3-ylmethyl)-4-piperidinyl]ethyl]-[1,3]dioxole[4,5- f] Preparation of isoindole-5,7-dione (compound 1-37)
- Example 51 6-[2-[l-(Pyridazin-3-ylmethyl)-4-piperidinyl]ethyl]spiro[[1,3]dioxole[4, Preparation of 5-f]isoindole-7,1'-cyclopropane]-5-one (Compound 1-38)
- Example 52 6-[2-[1-(1 ⁇ -pyrrol-2-ylmethyl)-4-piperidinyl]ethyl]spiro[[1,3]dioxole [4, Preparation of 5-f]isoindole-7,1'-cyclopropene]-5-one (Compound 1-39)
- 1H-pyrrol-2-ylmethanol can be obtained by reduction of 1H-pyrrole-2-carbaldehyde via sodium borohydride.
- H-5 1-40 Add 300 ml of absolute ethanol to the reaction flask, 10 g (0.029 mol) of compound ⁇ -5, 20 g (0.13 mol) of ethyl 5-methyl-1H-pyrrole-2-carboxylate, room temperature After stirring, 30 g (1.30 mol) of sodium metal was added in portions. After the addition, the temperature was raised to 60-70 ° C for 5 to 6 hours. The reaction was completed. Ethyl acetate and water were extracted and washed, and the organic layer was collected. It was dried, filtered, and the filtrate was concentrated to dryness.
- Scopolamine is a competitive antagonist of central M choline receptors, which blocks Ml and M2 receptors, causes memory impairment, and becomes a model of Alzheimer's disease.
- the drug of the formula (I) was screened by using donepezil hydrochloride (DPH) as a positive drug. After 3-5 days of dosing, the animals were tested for Morris water maze behavior.
- mice Male c57 mice, 22 ⁇ 2 g, animals were housed in clean-dark (10 h/14 h) clean-grade animal rooms, fed with free water, and started experimenting after one week of adaptive feeding;
- Animals were randomly divided into body weights, 15 in each group.
- the normal group, the scopolamine group, the donepezil hydrochloride group (DPH), and the compound of the formula (I) were intragastrically administered (10 ml/kg) daily, and the normal group and the model group were given an equal volume of vehicle.
- the Morris Water Maze consists of a circular pool, automatic image acquisition and processing system. After the animals enter the water, the monitoring device is started, the animal's movement trajectory is recorded, and the relevant parameters are automatically analyzed and reported after the experiment is completed.
- the Morris water fan cylindrical pool is divided into four equal-sized quadrants, with a platform placed in the center of the first quadrant, which remains unchanged throughout the behavioral test. Put a proper amount of water on the day before the experiment so that the platform is not under water l cm. Add white pigment (2 g/L) before the experiment to make the water in the pool milky white (the water in the pool is changed once a day during the experiment). The experimental training phase was continued for 5 days and trained twice a day. During training, scopolamine (1 mg/kg) was intraperitoneally injected 30 min before training, and the mice were placed in the pool from the third quadrant to the pool wall. Record the time it takes for the mouse to enter the water to find the underwater concealed platform and stand on it.
- Place navigation Used to measure the ability of mice to learn and remember water maze. Experiments were performed to record and record the route map and time required for the mouse to find and climb the platform, ie to record its latency.
- Spatial probe test Used to measure the ability of mice to maintain memory on the platform's spatial position after learning to find a platform. After the positioning navigation experiment is completed, the platform is removed, and the water is placed in the water from the same water inlet point, and the time of the first arrival at the original platform position and the number of crossing the original platform are measured.
- mice were decapitated, brain tissue was taken (operated on an ice tray), 10% tissue homogenate was prepared with pre-cooled saline, centrifuged (3000 rpm, lO min), supernatant The solution was tested for malondialdehyde (MDA) according to the kit.
- MDA malondialdehyde
- the model of learning and memory impairment induced by injection of ⁇ 1-42 into the lateral ventricle is the most commonly used animal model for evaluating whether a compound has improved learning and memory.
- the animal model significantly destroys the learning ability and memory function of the animal, and the mechanism of affecting memory is clear, the result is easy to repeat, and there is no obvious non-specific effect.
- Morris water maze test and lateral ventricle injection of A ⁇ 1-42 induced learning and memory impairment model were used to evaluate the learning and memory of rats at different concentrations (0.7 mg/Kg, 3.5 mg Kg 7 mg/g). Improvement.
- Experimental materials and grouping were used to evaluate the learning and memory of rats at different concentrations (0.7 mg/Kg, 3.5 mg Kg 7 mg/g). Improvement.
- mice SD, male (220 soil 20g), animals are kept in the light and dark alternate (12 h: 12 h) clean animal room, free to eat drinking water. The animals were tested after 3 days in the animal room to adapt to the environment.
- ⁇ ⁇ 1-42 is formulated into 2 ⁇ / ⁇ 1 according to the instructions.
- Donepezil hydrochloride control group donepezil hydrochloride (DPH) (3 mg/Kg) + lateral ventricle injection A ⁇ 1-42
- Experimental equipment Rat Morris water maze device, brain stereotaxic instrument.
- SD rats were randomly divided into normal control group, lateral ventricle injection ⁇ ⁇ 1-42 model group, positive control group (donepezil hydrochloride 3 mg/Kg) and test group 1-33 (0.7 mg/kg, 3.5 mg/Kg). And 7 mg/kg group); "In the lower control group, the lateral ventricle was injected with 5 ⁇ of normal saline, and the other groups were injected with ⁇ ⁇ 1-42 5 ⁇ /only. The rats were recovered for one week after the operation and subsequent experiments were performed.
- the normal control group and the lateral ventricle were injected with ⁇ ⁇ 1-42 model group to give the corresponding solvent every morning at a fixed time; the 1-33 group and the donepezil hydrochloride control group were given the corresponding doses of the drug for 8 days.
- the water maze experiment was started on the 5th day, and the formal water maze test was performed on the 9th day. Try.
- the acute toxicity test refers to the "Technical Guidelines for Acute Toxicity Test of Chemical Drugs", and the representative hydrochlorides of the compounds 1-29 of the present invention (1-33) and the hydrochlorides of the compounds 1-17 (1-34) The mice were subjected to preliminary acute toxicity experiments.
- Acute toxicity test of donepezil hydrochloride 1. Intravenous injection: Animals were divided into 6 groups of 5 each; the doses used in 6 groups were: 4.00 mg/kg, 3.60 mg/kg, 3.24 mg/kg, 2.92 mg/kg, 2.62 mg/kg and 2.36. Mg/kg. Each tail vein was injected once and observed for 1W.
- Intravenous injection Animals were divided into 6 groups of 5 each; the doses used in 6 groups were: 50.00 mg/kg, 40.00 mg kg, 32.00 mg/kg, 25.60 mg/kg, 20.48 mg/kg and 16.18 mg /kg. Each tail vein was injected once and observed for 1W.
- Intravenous injection Animals were divided into 5 groups of 5 each; the doses used in the 5 groups were: 25.60 mg/kg, 23.04 mg/kg, 20.25 mg/kg, 18.23 mg/kg and 16.40 mg/kg, respectively. Each tail vein was injected once and observed for 1 W.
- the toxicity and mortality of the animals after administration were observed, and the mortality was statistically analyzed.
- the results were analyzed by LD50 data processing software.
- Inhibition activity compared with donepezil hydrochloride, 1-17 and 1-29 or its hydrochloride (1-33) showed a stronger effect of improving learning and memory in the Morris water maze test, showing better In vivo efficacy; particularly striking is 1-29 or its hydrochloride (1-33), although the compound has a weaker acetylcholinesterase inhibitory activity in vitro, only about 10% of donepezil hydrochloride, but has a ratio Donepezil hydrochloride has better in vivo efficacy, and the antioxidant effect is stronger than donepezil hydrochloride.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201500866A UA113444C2 (xx) | 2012-07-03 | 2013-03-07 | Похідна бензодіоксолу, спосіб її одержання та її застосування |
SG11201500007WA SG11201500007WA (en) | 2012-07-03 | 2013-07-03 | Benzodioxole derivative and preparation method and use thereof |
EP13813363.2A EP2871184B1 (en) | 2012-07-03 | 2013-07-03 | Benzodioxole derivative and preparation method and use thereof |
JP2015518794A JP6113275B2 (ja) | 2012-07-03 | 2013-07-03 | ベンゾジオキソール誘導体ならびにその調製方法および使用 |
NZ703549A NZ703549A (en) | 2012-07-03 | 2013-07-03 | Benzodioxole derivative and preparation method and use thereof |
NO13813363A NO2871184T3 (zh) | 2012-07-03 | 2013-07-03 | |
AU2013286523A AU2013286523B2 (en) | 2012-07-03 | 2013-07-03 | Benzodioxole derivative and preparation method and use thereof |
EA201590074A EA026210B1 (ru) | 2012-07-03 | 2013-07-03 | Производное бензодиоксола, способ его получения и его применение |
CN201380033665.6A CN104395303B (zh) | 2012-07-03 | 2013-07-03 | 苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
KR1020157002550A KR101650776B1 (ko) | 2012-07-03 | 2013-07-03 | 벤조디옥솔 유도체 및 이의 제조방법과 용도 |
ES13813363.2T ES2645643T3 (es) | 2012-07-03 | 2013-07-03 | Derivado de benzodioxol y método de preparación y uso de los mismos |
CA2878000A CA2878000C (en) | 2012-07-03 | 2013-07-03 | Benzodioxole derivative and preparation method and use thereof |
MX2015000334A MX357774B (es) | 2012-07-03 | 2013-07-03 | Derivado de benzodioxol y metodo de preparacion y uso del mismo. |
IN11112DEN2014 IN2014DN11112A (zh) | 2012-07-03 | 2013-07-03 | |
BR112014032964A BR112014032964A2 (pt) | 2012-07-03 | 2013-07-03 | composto, composição farmacêutica, uso do composto, e, método para preparar o composto |
DK13813363.2T DK2871184T3 (da) | 2012-07-03 | 2013-07-03 | Benzodioxolderivat og fremgangsmåde til fremstilling og anvendelse deraf |
US14/411,783 US9346818B2 (en) | 2012-07-03 | 2013-07-03 | Benzodioxole derivative and preparation method and use thereof |
IL236395A IL236395A (en) | 2012-07-03 | 2014-12-22 | Benzodioxole derivatives and their method of preparation and use |
PH12015500012A PH12015500012A1 (en) | 2012-07-03 | 2015-01-05 | Benzodioxole derivative and preparation method and use thereof |
ZA2015/00692A ZA201500692B (en) | 2012-07-03 | 2015-01-30 | Benzodioxole derivative and preparation method and use thereof |
HK15103269.1A HK1202857A1 (zh) | 2012-07-03 | 2015-03-31 | 苯並間二氧雜環戊烯衍生物及其製備方法和用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210226125.7A CN103524515B (zh) | 2012-07-03 | 2012-07-03 | 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
CN201210226125.7 | 2012-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014005421A1 true WO2014005421A1 (zh) | 2014-01-09 |
Family
ID=49881293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/000813 WO2014005421A1 (zh) | 2012-07-03 | 2013-07-03 | 苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
Country Status (26)
Country | Link |
---|---|
US (1) | US9346818B2 (zh) |
EP (1) | EP2871184B1 (zh) |
JP (1) | JP6113275B2 (zh) |
KR (1) | KR101650776B1 (zh) |
CN (2) | CN103524515B (zh) |
AU (1) | AU2013286523B2 (zh) |
BR (1) | BR112014032964A2 (zh) |
CA (1) | CA2878000C (zh) |
CL (1) | CL2014003607A1 (zh) |
DK (1) | DK2871184T3 (zh) |
EA (1) | EA026210B1 (zh) |
ES (1) | ES2645643T3 (zh) |
HK (1) | HK1202857A1 (zh) |
IL (1) | IL236395A (zh) |
IN (1) | IN2014DN11112A (zh) |
MX (1) | MX357774B (zh) |
MY (1) | MY167075A (zh) |
NO (1) | NO2871184T3 (zh) |
NZ (1) | NZ703549A (zh) |
PE (1) | PE20150349A1 (zh) |
PH (1) | PH12015500012A1 (zh) |
PT (1) | PT2871184T (zh) |
SG (1) | SG11201500007WA (zh) |
UA (1) | UA113444C2 (zh) |
WO (1) | WO2014005421A1 (zh) |
ZA (1) | ZA201500692B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105859732A (zh) * | 2016-04-11 | 2016-08-17 | 浙江海正药业股份有限公司 | 制备ad-35的工艺 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103524515B (zh) * | 2012-07-03 | 2016-07-06 | 浙江海正药业股份有限公司 | 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
CA3023408A1 (en) * | 2016-05-13 | 2017-11-16 | DelNova, Inc. | Treating of side-effects resulting from chemodenervation |
CN110812358B (zh) * | 2018-08-10 | 2022-04-05 | 浙江海正药业股份有限公司 | 化合物ad-35在治疗与胃肠蠕动障碍相关疾病中的应用 |
CN113185447B (zh) * | 2021-05-06 | 2023-07-21 | 四川大学 | 邻苯二甲酰半胱酰胺类化合物、其制备方法和用途 |
CN115974839B (zh) * | 2021-12-24 | 2023-10-20 | 珠海市藤栢医药有限公司 | AChE/SERT双靶点抑制剂及其制备方法和用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895841A (en) | 1987-06-22 | 1990-01-23 | Eisai Co., Ltd. | Cyclic amine compounds with activity against acetylcholinesterase |
WO2000009483A2 (en) | 1998-08-17 | 2000-02-24 | Finetech Ltd. | Process and intermediates for production of donepezil and related compounds |
CN1426405A (zh) * | 2000-02-29 | 2003-06-25 | 三菱制药株式会社 | 新型环状酰胺衍生物 |
WO2005003092A1 (en) | 2003-07-01 | 2005-01-13 | Hetero Drugs Limited | Preparation of intermediates for acetyl cholinesterase inhibitors |
WO2005076749A2 (en) | 2004-02-11 | 2005-08-25 | Jubilant Organosys Limited | A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine |
WO2007077443A1 (en) | 2006-01-04 | 2007-07-12 | Cipla Limited | Process and intermediate for preparation of donepezil |
WO2007082731A1 (en) | 2006-01-18 | 2007-07-26 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
US20090137629A1 (en) * | 2002-01-22 | 2009-05-28 | Yoichi Iimura | Sigma receptor binding agent containing indanone derivative |
CN101626688A (zh) * | 2006-12-11 | 2010-01-13 | 雷维瓦药品公司 | 茚满酮基胆碱酯酶抑制剂的组合物、合成和使用方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4087541A (en) * | 1975-03-06 | 1978-05-02 | Boehringer Ingelheim Gmbh | 2-(Aralkylaminoalkyl)phthalimidines |
US5175157A (en) * | 1985-11-27 | 1992-12-29 | Boehringer Ingelheim Gmbh | Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them |
JPH0610496B2 (ja) * | 1987-09-17 | 1994-02-09 | ダイハツ工業株式会社 | 車両用自動変速機のクラッチ構造 |
JP2777159B2 (ja) * | 1988-12-22 | 1998-07-16 | エーザイ株式会社 | 環状アミン誘導体を含有する医薬 |
CN103524515B (zh) * | 2012-07-03 | 2016-07-06 | 浙江海正药业股份有限公司 | 具有乙酰胆碱酯酶抑制活性的苯并间二氧杂环戊烯衍生物及其制备方法和用途 |
-
2012
- 2012-07-03 CN CN201210226125.7A patent/CN103524515B/zh active Active
-
2013
- 2013-03-07 UA UAA201500866A patent/UA113444C2/uk unknown
- 2013-07-03 AU AU2013286523A patent/AU2013286523B2/en active Active
- 2013-07-03 US US14/411,783 patent/US9346818B2/en active Active
- 2013-07-03 ES ES13813363.2T patent/ES2645643T3/es active Active
- 2013-07-03 NZ NZ703549A patent/NZ703549A/en not_active IP Right Cessation
- 2013-07-03 CA CA2878000A patent/CA2878000C/en active Active
- 2013-07-03 BR BR112014032964A patent/BR112014032964A2/pt not_active Application Discontinuation
- 2013-07-03 DK DK13813363.2T patent/DK2871184T3/da active
- 2013-07-03 MY MYPI2014704095A patent/MY167075A/en unknown
- 2013-07-03 IN IN11112DEN2014 patent/IN2014DN11112A/en unknown
- 2013-07-03 PE PE2014002581A patent/PE20150349A1/es active IP Right Grant
- 2013-07-03 EA EA201590074A patent/EA026210B1/ru not_active IP Right Cessation
- 2013-07-03 CN CN201380033665.6A patent/CN104395303B/zh active Active
- 2013-07-03 NO NO13813363A patent/NO2871184T3/no unknown
- 2013-07-03 KR KR1020157002550A patent/KR101650776B1/ko active IP Right Grant
- 2013-07-03 JP JP2015518794A patent/JP6113275B2/ja active Active
- 2013-07-03 SG SG11201500007WA patent/SG11201500007WA/en unknown
- 2013-07-03 MX MX2015000334A patent/MX357774B/es active IP Right Grant
- 2013-07-03 WO PCT/CN2013/000813 patent/WO2014005421A1/zh active Application Filing
- 2013-07-03 PT PT138133632T patent/PT2871184T/pt unknown
- 2013-07-03 EP EP13813363.2A patent/EP2871184B1/en active Active
-
2014
- 2014-12-22 IL IL236395A patent/IL236395A/en not_active IP Right Cessation
- 2014-12-31 CL CL2014003607A patent/CL2014003607A1/es unknown
-
2015
- 2015-01-05 PH PH12015500012A patent/PH12015500012A1/en unknown
- 2015-01-30 ZA ZA2015/00692A patent/ZA201500692B/en unknown
- 2015-03-31 HK HK15103269.1A patent/HK1202857A1/zh unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895841A (en) | 1987-06-22 | 1990-01-23 | Eisai Co., Ltd. | Cyclic amine compounds with activity against acetylcholinesterase |
US5100901A (en) | 1987-06-22 | 1992-03-31 | Eisai Co., Ltd. | Cyclic amine compounds and pharmaceutical use |
WO2000009483A2 (en) | 1998-08-17 | 2000-02-24 | Finetech Ltd. | Process and intermediates for production of donepezil and related compounds |
CN1426405A (zh) * | 2000-02-29 | 2003-06-25 | 三菱制药株式会社 | 新型环状酰胺衍生物 |
US20090137629A1 (en) * | 2002-01-22 | 2009-05-28 | Yoichi Iimura | Sigma receptor binding agent containing indanone derivative |
WO2005003092A1 (en) | 2003-07-01 | 2005-01-13 | Hetero Drugs Limited | Preparation of intermediates for acetyl cholinesterase inhibitors |
WO2005076749A2 (en) | 2004-02-11 | 2005-08-25 | Jubilant Organosys Limited | A novel process for the preparation of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine |
WO2007077443A1 (en) | 2006-01-04 | 2007-07-12 | Cipla Limited | Process and intermediate for preparation of donepezil |
WO2007082731A1 (en) | 2006-01-18 | 2007-07-26 | Siena Biotech S.P.A. | Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof |
CN101626688A (zh) * | 2006-12-11 | 2010-01-13 | 雷维瓦药品公司 | 茚满酮基胆碱酯酶抑制剂的组合物、合成和使用方法 |
Non-Patent Citations (3)
Title |
---|
2011 ALZHEIMER' DISEASE FACTS AND FIGURES, ALZHEIMER'S & DEMENTIA, vol. 7, no. 2, 2011, pages 208 |
See also references of EP2871184A4 |
SUGIMOTO ET AL., J. MED. CHEM., vol. 38, 1995, pages 4821 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105859732A (zh) * | 2016-04-11 | 2016-08-17 | 浙江海正药业股份有限公司 | 制备ad-35的工艺 |
WO2017177816A1 (zh) * | 2016-04-11 | 2017-10-19 | 浙江海正药业股份有限公司 | 制备ad-35的工艺 |
US10399992B2 (en) | 2016-04-11 | 2019-09-03 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Process for preparing AD-35 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014005421A1 (zh) | 苯并间二氧杂环戊烯衍生物及其制备方法和用途 | |
RU2125051C1 (ru) | Производные дифенила, производное фенилпиперазина и способ лечения | |
US5981520A (en) | Piperazino derivatives as neurokinin antagonists | |
DE602004010785T2 (de) | 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung | |
KR20190035925A (ko) | 아미노-피롤로피리미디논 화합물 및 이의 사용 방법 | |
US5977131A (en) | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents | |
TW200815431A (en) | Azabenzimidazolyl compounds | |
TWI291466B (en) | Piperidine derivatives, process for their preparation, pharmaceutical composition containing them and their medical use | |
JPH11502861A (ja) | サブスタンスpアンタゴニストとしての置換ベンゾラクタム化合物 | |
NO177590B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive cykliske aminforbindelser | |
US20230159530A1 (en) | Morphinan derivative | |
SK96194A3 (en) | Bicyclic nitrogen containing compounds and pharmaceutical agents on their basis | |
TW200902518A (en) | Substituted heterocyclic derivatives and their pharmaceutical use and compositions | |
JP2004513944A (ja) | 神経系障害の治療に有用な新規なアミドアルキル−ピペリジンおよびアミドアルキル−ピペラジン誘導体 | |
CA3068842A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
CA2975973A1 (en) | Amide compounds as 5-ht4 receptor agonists | |
US20240083907A1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
TW201118069A (en) | Spirolactam derivatives and uses of same | |
JPWO2004029056A1 (ja) | [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体 | |
TW200904449A (en) | Dibenzo[b,f][1,4]oxazapine compounds | |
RU2605931C2 (ru) | Фторзамещенные циклические аминосоединения и способы их получения, фармацевтические композиции и их применения | |
TW509692B (en) | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones | |
JPWO2008108309A1 (ja) | 縮環ピリジン誘導体 | |
JPH0319236B2 (zh) | ||
US20220119351A1 (en) | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13813363 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201408199 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 2015518794 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2878000 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14411783 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014003607 Country of ref document: CL Ref document number: P1472/2014 Country of ref document: AE Ref document number: 002581-2014 Country of ref document: PE |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015500012 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/000334 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201590074 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20157002550 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2013813363 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201500866 Country of ref document: UA Ref document number: 2013813363 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013286523 Country of ref document: AU Date of ref document: 20130703 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014032964 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014032964 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141230 |